Skip Navigation


Annals of Oncology Advance Access originally published online on July 27, 2006
Annals of Oncology 2006 17(11):1665-1672; doi:10.1093/annonc/mdl174
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
17/11/1665    most recent
mdl174v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (3)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Ichikawa, W
Right arrow Articles by Sasaki, Y
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ichikawa, W
Right arrow Articles by Sasaki, Y
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2006 European Society for Medical Oncology

gastrointestinal tumors

Correlation between tumor response to first-line chemotherapy and prognosis in advanced gastric cancer patients

W Ichikawa* and Y Sasaki

Department of Clinical Oncology, Saitama Medical School, Saitama 350–049, Japan

*Correspondence to: Dr W. Ichikawa, Department of Clinical Oncology, Saitama Medical School, 38, Moro-Hongo, Moroyama, Iruma, Saitama 350–049, Japan. Tel: +81-49-276-1711; Fax: +81-49-276-1711; E-mail: wataru{at}saitama-med.ac.jp

Background: In advanced gastric cancer, the relationship between tumor response and prognosis is far from clear.

Methods: We performed a pooled analysis on published data from 4593 patients in 25 randomized trials of first-line chemotherapy for advanced gastric cancer. A weighed analysis was used to investigate the correlation between objective response rate (RR) and time to progression (TTP) and overall survival time (OS).

Results: A moderate correlation was found between RR and TTP and OS (r = 0.49 and r = 0.45, respectively) in all 25 trials. In treatment arms without new drugs including irinotecan, taxanes, or oxaliplatin, RR also was associated with TTP and OS (r = 0.56 and r = 0.47, respectively). However, no association between RR and OS was found, whereas there was a moderate correlation between RR and TTP (r = 0.41) in treatment arms using new drugs.

Conclusions: Our results indicated that response to treatment was related to TTP and OS. The potential role of objective response as a surrogate in chemotherapy trials of advanced gastric cancer warrants further investigation, especially with regard to treatment with new drugs.

Key words: gastric cancer, overall survival, response rate, time to progression


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 JCOHome page
A. D. Wagner, U. Wedding, O. Kuss, and K. Hoffken
Docetaxel for Advanced Gastric Cancer?
J. Clin. Oncol., June 10, 2007; 25(17): 2490 - 2491.
[Full Text] [PDF]

Home page
 JCOHome page
J. A. Ajani
In Reply
J. Clin. Oncol., June 10, 2007; 25(17): 2491 - 2493.
[Full Text] [PDF]

Home page
 Ann OncolHome page
J Lee, T Lim, J. Uhm, K. Park, S. Park, S. Lee, J. Park, Y. Park, H. Lim, T. Sohn, et al.
Prognostic model to predict survival following first-line chemotherapy in patients with metastatic gastric adenocarcinoma
Ann. Onc., May 1, 2007; 18(5): 886 - 891.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.